Answers are grounded in this paper and cite their sources.
Background/Objectives: The aim of this study was to determine biomarkers of cancer cachexia (CC) and evaluate its association with long-term outcomes in patients with head and neck squamous cell carcinoma (HNSCC) undergoing ablative surgery with anterolateral thigh (ALT) reconstruction. Methods: Patients with mucosal HNSCC who had ablative surgery with ALT reconstruction within our health system from January 2014 to April 2024 without additional risk factors for sarcopenia were evaluated for demographics, physical and tumor characteristics, oncologic treatment, and outcomes relative to CC, as defined by pre-operative weight loss, BMI and/or muscle loss. Results: Among 117 patients, 60% met criteria for CC at the time of surgery. T4 stage (odds ratio (OR) 2.5, 95%CI 1.2–5.2), presence of nodal disease (OR 2.1, 95%CI 1.0–4.7), stage IV disease (OR 3.9, 95%CI 1.8–8.8), lower cancer cachexia index (CXI, p < 0.0001), higher neutrophil-to-lymphocyte ratio (NLR, p = 0.0006), and lower hemoglobin levels (p = 0.0007) were associated with CC. The CC group experienced significantly worse disease-free survival (HR = 2.0, 95%CI 1.2–3.4) and overall survival (HR = 2.2, 95%CI 1.2–3.6). Conclusions: Cancer cachexia is common in patients with HNSCC undergoing ablative surgery with ALT reconstruction and is associated with markers of systemic inflammation and worse long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Eggers et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: